Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 27, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Canepa John J (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.55	2030-12-14	Common Stock (322710)		Direct

Footnotes

F1: This option shall vest and become exercisable as follows: 35% shall vest on December 1, 2021; 35% shall vest in equal monthly installments between January 1, 2022 and December 1, 2022; 15% shall vest in equal monthly installments between January 1, 2023 and December 1, 2023; and the last 15% shall vest in equal monthly installments between January 1, 2024 and December 1, 2024.